Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A
Autore:
Sarchielli, P; Critelli, A; Greco, L; Sokola, E; Floridi, A; Gallai, V;
Indirizzi:
Univ Perugia, Dept Internal Med, Biochem Lab, I-06100 Perugia, Italy Univ Perugia Perugia Italy I-06100 , Biochem Lab, I-06100 Perugia, Italy Univ Perugia, Dept Neurosci, Neurol Clin, I-06100 Perugia, Italy Univ Perugia Perugia Italy I-06100 , Neurol Clin, I-06100 Perugia, Italy
Titolo Testata:
CYTOKINE
fascicolo: 5, volume: 14, anno: 2001,
pagine: 294 - 298
SICI:
1043-4666(20010607)14:5<294:EOTMBP>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
NECROSIS-FACTOR-ALPHA; MESSENGER-RNA EXPRESSION; INTERFERON BETA-1A; GUIDELINES; CYTOKINES; GAMMA;
Keywords:
multiple sclerosis; TNF-alpha; mRNA; IFN-beta 1a;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: Sarchielli, P Policlin Monteluce, Dept Neurosci, Neurol Clin, Via E Dal Pozzo, I-06126 Perugia, Italy Policlin Monteluce Via E Dal Pozzo Perugia Italy I-06126 ly
Citazione:
P. Sarchielli et al., "Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A", CYTOKINE, 14(5), 2001, pp. 294-298

Abstract

The aim of the present study was to verify the expression of tumour necrosis factor (TNF)-alpha mRNA by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) in unstimulated peripheral blood mononuclear cells (MNCs) of 15 relapsing-remitting multiple sclerosis (MS) patients who underwent treatment with IFN-beta 1a (6 millions of international units (MIU) i.m. once a week) and in 15 untreated MS patients matched for age and expanded disability status score (EDSS). At the same time the expression of TNF-alpha mRNA was assessed in 10 healthy age-matched control subjects. All MS patients were assessed at the basal time and after 6 months. At the basal time, the band of TNF-alpha mRNA was detectable in 12 out of the 15 untreated patients and in 13 out of the 15 patients who underwent IFN-beta 1a treatment. The higher TNF-alpha mRNA was evident in patients with gadolinium-enhancing lesions. At the 6-month follow-up, 13 out of the 15 untreated patients still had detectable values of TNF-alpha mRNA and no significant difference emerged when compared with basal time. On the contrary, the expression of TNF-alpha mRNA was absent at the same time in nine out of the 15 patients treated with IFN-beta 1a, A longitudinal analysis carried out monthly in eight MS patients (four untreated and four treated) revealed a transientincrease in TNF-alpha mRNA expression in MNCs of all four treated patientsin the first 3 months, supporting previous findings of an early immunoenhancing effect of IFN-beta la, This early activation is followed by an inhibitory effect of IFN-beta 1a on TNF-alpha mRNA expression in about 2/3 of treated MS patients when assessed at 6 months. Further long-term studies are needed to confirm this immunomodulatory effect of IFN-beta 1a not only on TNF-alpha but also on other cytokines of Th-1 and Th-2 types. (C) 2001 Academic Press.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 21:51:20